The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma.
作者信息
Teng Margaret L P, Chan Kai En, Tan Darren J H, Huang Daniel Q
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
出版信息
Hepatobiliary Surg Nutr. 2022 Oct;11(5):735-737. doi: 10.21037/hbsn-22-362.
Abstract
摘要
相似文献
1
The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma.非酒精性脂肪性肝病相关肝细胞癌日益增长的威胁
Hepatobiliary Surg Nutr. 2022 Oct;11(5):735-737. doi: 10.21037/hbsn-22-362.
3
[Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].[非酒精性脂肪性肝病与肝细胞癌 - 2016年]
Orv Hetil. 2016 Jun 19;157(25):987-94. doi: 10.1556/650.2016.30425.
4
Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.影响脂肪性肝炎中肝细胞癌的代谢因素。
Liver Int. 2019 Mar;39(3):531-539. doi: 10.1111/liv.14002. Epub 2018 Dec 2.
5
Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的进行性肝纤维化。
Cells. 2021 Dec 2;10(12):3401. doi: 10.3390/cells10123401.
6
Hepatocellular carcinoma and non-alcoholic fatty liver disease.肝细胞癌与非酒精性脂肪性肝病。
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8. Epub 2019 Nov 7.
7
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
8
Human vascular adhesion proteın-1 (VAP-1): serum levels for hepatocellular carcinoma in non-alcoholic and alcoholic fatty liver disease.人血管黏附蛋白-1（VAP-1）：非酒精性和酒精性脂肪性肝病中肝细胞癌的血清水平。
World J Surg Oncol. 2010 Sep 17;8:83. doi: 10.1186/1477-7819-8-83.
9
Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?对于酒精性肝病或非酒精性脂肪性肝病患者，你应该提倡进行肝细胞癌监测吗？
Clin Mol Hepatol. 2020 Apr;26(2):183-184. doi: 10.3350/cmh.2020.0042. Epub 2020 Mar 12.
10
Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的肝细胞癌。
Curr Pharm Des. 2020;26(32):3909-3914. doi: 10.2174/1381612826666200429093648.
引用本文的文献
1
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.代谢相关脂肪性肝病患者发生肝功能障碍的演变及其与肝细胞癌风险的关系：一项全国性队列研究。
Clin Mol Hepatol. 2024 Jul;30(3):487-499. doi: 10.3350/cmh.2024.0145. Epub 2024 May 7.
本文引用的文献
1
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH.男性和女性肝癌的全球负担：病因基础的变化及非酒精性脂肪性肝炎（NASH）的贡献日益增加。
Hepatology. 2023 Apr 1;77(4):1150-1163. doi: 10.1002/hep.32758. Epub 2022 Sep 12.
2
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.2010 年至 2019 年全球肝癌流行病学变化：NASH 是肝癌增长最快的病因。
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
3
NAFLD-related hepatocellular carcinoma: The growing challenge.非酒精性脂肪性肝病相关肝细胞癌：日益严峻的挑战。
Hepatology. 2023 Jan 1;77(1):323-338. doi: 10.1002/hep.32542. Epub 2022 Nov 8.
4
Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.米兰标准内肝细胞癌的肝切除术与肝移植术对比：18421例患者的荟萃分析
Hepatobiliary Surg Nutr. 2022 Feb;11(1):78-93. doi: 10.21037/hbsn-21-350.
5
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.非酒精性脂肪性肝病相关肝细胞癌的临床特征、监测、治疗分配和结局：系统评价和荟萃分析。
Lancet Oncol. 2022 Apr;23(4):521-530. doi: 10.1016/S1470-2045(22)00078-X. Epub 2022 Mar 4.
6
Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies.近十年肝癌切除术后的全球和区域长期生存：110 项研究的荟萃分析。
Hepatol Commun. 2022 Jul;6(7):1813-1826. doi: 10.1002/hep4.1923. Epub 2022 Mar 2.
7
Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study.在非酒精性脂肪性肝病肝硬化中，超声与简化 MRI 最优检查的 HCC 筛查比较效果：一项前瞻性研究。
Aliment Pharmacol Ther. 2022 Apr;55(7):820-827. doi: 10.1111/apt.16844. Epub 2022 Feb 28.
8
UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.UNOS 肝癌肝移植降期标准：25 项研究的系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1475-1484. doi: 10.1016/j.cgh.2022.02.018. Epub 2022 Feb 16.
9
Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study.肝硬化患者肝癌监测中超声质量与检测性能之间的关联：一项回顾性队列研究。
Aliment Pharmacol Ther. 2022 Mar;55(6):683-690. doi: 10.1111/apt.16779. Epub 2022 Feb 15.
10
Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.非酒精性脂肪性肝病中的肝细胞癌——临床医生面临的新挑战综述
Hepatobiliary Surg Nutr. 2021 Jan;10(1):59-75. doi: 10.21037/hbsn.2019.08.08.
Zotero 插件